A practical reference on tuftsin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
| Property | Value | Notes |
|---|---|---|
| Solubility | Freely soluble in water | Also in aqueous buffers |
| Typical purity (HPLC) | 95 percent or higher | Lot-dependent |
| Dry powder storage | Minus 20 degrees Celsius | Sealed, dry, protected from light |
| Solution storage | 2 to 8 degrees Celsius | Short-term use |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF |
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
In 2001, the entire line was facelifted with new styling, a revised suspension, and a new audio system. For North America, ES models received rear disc brakes and a stiffer suspension. The 1.8 L engine was increased to 2.0 L for the ES models, and was optional on the LX model, becoming the 2.0LX. The standard 2001 Protegé LX engine was the carryover 1.6 L ZM-DE. A 2.0-litre, petrol engine appeared in 2001 on the Japanese market Sport 20. In 1999, Ford of Japan ceased to market Mazda-based models, and the Ford Laser, along with the Ixion, Telstar, and Festiva, was discontinued.
=== An–At === Rudolph John Anderson (1879–1961). American biochemist graduated with a PhD from Cornell University Medical College. Member Natl. Acad. Sci. USA. Thomas F. Anderson (1911–1991). American biophysical chemist and geneticist at the University of Pennsylvania, a pioneer in applying electron microscopy to bacteria and viruses. Member Natl. Acad. Sci. USA. Mortimer Louis Anson (1901–1968). American biochemist and protein chemist, the first to propose that protein folding was reversible. Akira Arimura (1923–2007). Japanese biochemist and endocrinologist at Tulane University who studied hormones. Shy Arkin (b. 1965). Israeli biochemist at the Hebrew University of Jerusalem, working on structural analysis of transmembrane proteins Judy Armitage FRS (b. 1951). British biochemist at Oxford University, working on motion of bacteria by flagellar rotation. Frances Arnold (b. 1956). American biochemist and biochemical engineer at Caltech, pioneer of the use of directed evolution to engineer enzymes. Nobel Prize for Chemistry (2018). Member Natl. Acad. Sci. USA. Ruth Arnon (b. 1933) Israeli biochemist at the Weizmann Institute, who works on researching anti-cancer and influenza vaccinations. She participated in developing the multiple sclerosis drug Copaxone. President of the Israel Academy of Sciences and Humanities. Helen Asemota (20th–21st century). Nigerian biochemist at the University of the West Indies, Jamaica, who studied the molecular genetics and metabolism of the browning of yam tubers in storage. Gilbert Ashwell (1916–2014).
One barn is 10−28 square metres, about the cross-sectional area of a uranium nucleus. The name probably derives from early neutron-deflection experiments, when the uranium nucleus was described, and the phrases "big as a barn" and "hit a barn door" were used. Barn are typically used for cross sections in nuclear and particle physics. Additional units include the microbarn (or "outhouse") and the yoctobarn (or "shed").
=== Sources to people === Food, drinking water, outdoor air, indoor air, dust, and food packagings are all implicated as sources of PFOA to people. However, it is unclear which exposure routes dominate because of data gaps. When water is a source, blood levels are approximately 100 times higher than drinking water levels. People who lived in the PFOA-contaminated area around DuPont's Washington Works facility were found to have higher levels of PFOA in their blood from drinking water. The highest PFOA levels in drinking water were found in the Little Hocking water system, with an average concentration of 3.55 parts per billion during 2002–2005. Individuals who drank more tap water, ate locally grown fruits and vegetables, or ate local meat, were all associated with having higher PFOA levels. Residents who used water carbon filter systems had lower PFOA levels. In Jersey, UK, 18% of residents of an area were found to have elevated levels of PFOA, downstream from 3M fire retardant tests in weekly fire-service practice from the 1960s to the mid 1990s. Bloodletting is used for these residents at a cost of $4500 per patient. The potatoes of the island were found to contain 10x the EU limit of PFOS.
== Concept == Protein nutrition is complex because any proteinogenic amino acid may be the limiting factor in metabolism. Mixing livestock feeds can optimize for growth, or minimize cost while maintaining adequate growth. Similarly, human nutrition is subject to Liebig's law of the minimum: The lowest level of one of the essential amino acids will be the limiting factor in metabolism.
Sources: en.wikipedia.org
Many of the targets were chosen only secondarily to contribute to the military defeat of Iraq ... Military planners hoped the bombing would amplify the economic and psychological impact of international sanctions on Iraqi society ... They deliberately did great harm to Iraq's ability to support itself as an industrial society ... In the Jan/Feb 1995 edition of Foreign Affairs, French diplomat Eric Rouleau wrote:
Although it is not entirely clear which gene causes the resistance phenotype, there is strong evidence supporting the correlation between a mutation in the membrane transporter ABCC2 and Bt resistance. Other studies with greenhouse-evolved population of Bt resistant cabbage looper demonstrate that the downregulation of the aminopeptidase N, APN1, results in its resistance.
On April 25, 2023, President Joe Biden officially announced his re-election campaign, confirming that Vice President Kamala Harris would remain his running mate. Concerns about Biden's age were prominent, given that he was the oldest person to assume the office at age 78, which would make him 82 at the end of his first term and 86 at the end of a potential second term. An April 2023 poll indicated that 70 percent of Americans, including 51 percent of Democrats, believed Biden should not seek a second term, with nearly half citing his age as the reason. Biden's approval rating stood at 41 percent, with 55 percent disapproving. Speculation also arose that Biden might face a primary challenge from the Democratic Party's progressive faction; however, after Democrats outperformed expectations in the 2022 midterm elections, many believed Biden's chances of securing the party's nomination had increased. On July 28, 2022, Representative Dean Phillips of Minnesota became the first incumbent Democratic member of Congress to say Biden should not run for re-election and called for "generational change", pointing to Biden's age. Despite a handful of primary challengers, including Representative Dean Phillips, Robert F. Kennedy Jr., Marianne Williamson, and Jason Palmer, Biden easily became the party's presumptive nominee on March 12, 2024. Palmer, who won the American Samoa caucuses, became the first candidate to win a contested primary against an incumbent president since Ted Kennedy in 1980.
=== EC 1.8.4 With a disulfide as acceptor === EC 1.8.4.1: glutathione—homocystine transhydrogenase EC 1.8.4.2: protein-disulfide reductase (glutathione) EC 1.8.4.3: glutathione—CoA-glutathione transhydrogenase EC 1.8.4.4: glutathione—cystine transhydrogenase EC 1.8.4.5: Now EC 1.8.4.13, L-methionine (S)-S-oxide reductase and EC 1.8.4.14, L-methionine (R)-S-oxide reductase EC 1.8.4.6: due to EC 1.8.4.11, peptide-methionine (S)-S-oxide reductase EC 1.8.4.7: enzyme-thiol transhydrogenase (glutathione-disulfide) EC 1.8.4.8: phosphoadenylyl-sulfate reductase (thioredoxin) EC 1.8.4.9: adenylyl-sulfate reductase (glutathione) EC 1.8.4.10: adenylyl-sulfate reductase (thioredoxin) EC 1.8.4.11: peptide-methionine (S)-S-oxide reductase EC 1.8.4.12: peptide-methionine (R)-S-oxide reductase EC 1.8.4.13: L-methionine (S)-S-oxide reductase EC 1.8.4.14: L-methionine (R)-S-oxide reductase EC 1.8.4.15: protein dithiol oxidoreductase (disulfide-forming) EC 1.8.4.16: thioredoxin:protein disulfide reductase
Sources: en.wikipedia.org
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.
Freeze-dried material is kept frozen, often at minus 20 degrees Celsius, and protected from light and moisture. Dissolved peptide is refrigerated for short-term use. Repeated freeze-thaw cycles are avoided.
A certificate of analysis typically lists purity by HPLC, the confirmed mass, appearance, and sometimes water or counter-ion content. It documents results for a specific batch. Details vary by supplier.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.